Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
65.24
+0.07 (0.11%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Incyte Revenue
Incyte had revenue of $1.04B in the quarter ending June 30, 2024, with 9.34% growth. This brings the company's revenue in the last twelve months to $3.86B, up 9.78% year-over-year. In the year 2023, Incyte had annual revenue of $3.70B with 8.87% growth.
Revenue (ttm)
$3.86B
Revenue Growth
+9.78%
P/S Ratio
3.76
Revenue / Employee
$1,528,135
Employees
2,524
Market Cap
12.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG | 20.80B |
DaVita | 12.52B |
Solventum | 8.21B |
Smith & Nephew | 5.64B |
Dr. Reddy's Laboratories | 3.46B |
Exact Sciences | 2.61B |
BioMarin Pharmaceutical | 2.59B |
Royalty Pharma | 2.24B |
INCY News
- 3 hours ago - Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List - Business Wire
- 14 days ago - Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program - Business Wire
- 16 days ago - Incyte to Report Third Quarter Financial Results - Business Wire
- 16 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress - Business Wire
- 5 weeks ago - Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease - PRNewsWire
- 5 weeks ago - Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets - Benzinga